In vitro activity of the New Echinocandin Antifungal, MK-0991, against common and uncommon clinical isolates of Candida species

F. Barchiesi, A. M. Schimizzi, A. W. Fothergill, G. Scalise, M. G. Rinaldi

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

A broth macrodilution method, performed as recommended by the National Committee for Clinical Laboratory Standards, was used for comparative testing of the new echinocandin antifungal agent MK-0991 and fluconazole against 50 yeast isolates belonging to 12 species of Candida. MK-0991 was shown to be highly effective against both fluconazole-susceptible and -resistant Candida spp., yielding minimum inhibitory concentrations ranging from ≤ 0.19 to 0.78 μg/ml. Fungicidal activity was exerted at ≤ 1.5 μg/ml for 73% of the isolates tested. This study suggests that MK-0991 has significant potential for clinical development.

Original languageEnglish (US)
Pages (from-to)302-304
Number of pages3
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Volume18
Issue number4
DOIs
StatePublished - 1999

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vitro activity of the New Echinocandin Antifungal, MK-0991, against common and uncommon clinical isolates of Candida species'. Together they form a unique fingerprint.

Cite this